Dorothea Rudolph Selected Research

BI 6727

1/2018	Synergistic activity of BET inhibitor BI 894999 with PLK inhibitor volasertib in AML in vitro and in vivo.
3/2015	Efficacy and mechanism of action of volasertib, a potent and selective inhibitor of Polo-like kinases, in preclinical models of acute myeloid leukemia.
5/2009	BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Dorothea Rudolph Research Topics

Disease

5	Neoplasms (Cancer) 01/2019 - 05/2009
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2018 - 03/2015
1	Lymphoma (Lymphomas) 09/2017
1	Carcinogenesis 09/2017
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 09/2017
1	Melanoma (Melanoma, Malignant) 10/2016
1	Colorectal Neoplasms (Colorectal Cancer) 05/2009

Drug/Important Bio-Agent (IBA)

3	BI 6727IBA 01/2018 - 05/2009
1	Pharmaceutical PreparationsIBA 01/2019
1	BI 894999IBA 01/2018
1	Phosphotransferases (Kinase)IBA 01/2018
1	Transcription Factors (Transcription Factor)IBA 09/2017
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 10/2016
1	Aurora KinasesIBA 10/2016
1	Polo-like KinasesIBA 03/2015
1	taxaneIBA 05/2009
1	Antimitotic AgentsIBA 05/2009
1	EnzymesIBA 05/2009

Therapy/Procedure

1	Therapeutics 09/2017
1	Drug Therapy (Chemotherapy) 05/2009